10x Genomics Inc Ordinary Shares - Class A (TXG)

Industry Health Information Services


This stock can be held in an Investment ISA and an Investment Account
Sell

$8.70

Buy

$8.90

arrow-up$0.14 (+1.62%)

Prices updated at 10 May 2025, 00:44 EDT
| Prices minimum 15 mins delay
|
Prices in USD

Sector
Healthcare
Industry
Health Information Services
Chairman
Mr. John R. Stuelpnagel, D.V.M.
CEO
Dr. Serge Saxonov, PhD
Most recent earnings
31 Dec 2024
Fiscal year end
31 Dec 2024
Employees
1,306
Head office
6230 Stoneridge Mall Road
Pleasanton
United States
94588
mobile
+1 925 401-7300
letter
investors@10xgenomics.com

Key personnel

Salary
Mr. Eric S. Whitaker
Chief Legal Officer
0.48m
Mr. John R. Stuelpnagel, D.V.M.
Chairman of the Board
0.13m
Ms. Kimberly J. Popovits
Independent Director
0.07m
Mr. Alan V. Mateo
Independent Director
0.03m
Dr. Shehnaaz Suliman, M.D.
Independent Director
0.07m
Dr. Serge Saxonov, PhD
Chief Executive Officer and Director
0.63m
Dr. Benjamin J. Hindson, PhD
Director, Chief Scientific Officer and President
0.49m
Mr. Sridhar Kosaraju
Independent Director
0.08m
Mr. Adam S. Taich
Chief Financial Officer and Principal Accounting Officer
0.19m
Dr. Sarah A. Teichmann
Independent Director
0.03m

Top 5 shareholders

No. of shares
FMR Inc13,454,434
Fidelity Management and Research Company13,454,434
ARK Investment Management LLC11,944,057
Vanguard Group Inc. ( Junked)10,972,930
Vanguard Group Inc10,933,549

Director dealings

Action
23 Dec 2024-
23 Dec 2024-
22 Nov 2024-
21 Nov 2024-
22 Nov 2024-
14 Nov 2024-
23 Oct 2024-
17 Mar 2025-
30 Aug 2024-
22 Aug 2024-
22 Aug 2024-
22 Aug 2024-
31 Jul 2024-
11 Jun 2024-
11 Jun 2024-
11 Jun 2024-
11 Jun 2024-
29 May 2024-
22 May 2024-
22 May 2024-
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.